Kiruthika Balasundaram in New York, New York

Medical School: Sorry, her university is not listed
Graduation Year: 2004
The Primary Medical Specialty for Kiruthika Balasundaram is listed as: Cardiovascular Disease (cardiology)
Approximate Years of Experience: 20
PAC (PECOS ID)#: 0244425866
NPI #: 1447442082
NPI Created On: 08/17/2007
NPI Last Updated Listed as: 07/21/2022
Primary Taxonomy Code: 207R00000X
License Number:
271365
Listed Gender: Female

Services and Procedures include:

1. Nuclear medicine study of vessels of heart using drugs or exercise multiple studies
2. Routine ekg using at least 12 leads including interpretation and report
3. Exercise or drug-induced heart and blood vessel stress test with ekg monitoring, physician supervision, interpretation, and report
4. Heart rhythm tracing, computer analysis, and interpretation of patient-triggered events greater than 24-hour ekg up to 30 days
5. Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function
6. Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function
7. Doppler ultrasound study of heart blood flow, valves, and chambers
8. Doppler ultrasound study of color-directed heart blood flow, rate, and valve function
9. Ultrasound examination and continuous monitoring of the heart performed during rest, exercise, and/or drug-induced stress with interpretation and report
10. New patient office or other outpatient visit, typically 45 minutes
11. Established patient office or other outpatient visit, typically 15 minutes
12. Established patient office or other outpatient, visit typically 25 minutes
13. Initial hospital inpatient care, typically 70 minutes per day
14. Subsequent hospital inpatient care, typically 25 minutes per day
15. Subsequent hospital inpatient care, typically 35 minutes per day
16. Physician telephone patient service, 5-10 minutes of medical discussion
17. Physician telephone patient service, 11-20 minutes of medical discussion
18. Technetium tc-99m sestamibi, diagnostic, per study dose
19. Injection, regadenoson, 0.1 mg
20. Injection, perflutren lipid microspheres, per ml